The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma.
暂无分享,去创建一个
[1] P. Katsimbri. The biology of normal bone remodelling , 2017, European journal of cancer care.
[2] S. Avnet,et al. Mesenchymal stroma: Role in osteosarcoma progression. , 2017, Cancer letters.
[3] M. Donia,et al. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model , 2017, Nature Communications.
[4] Jun Yan,et al. γδ T Cells: Unexpected Regulators of Cancer Development and Progression. , 2017, Trends in cancer.
[5] Mei Zhang,et al. Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis , 2017, Oncotarget.
[6] S. Dry,et al. A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology , 2017, Oncotarget.
[7] C. D. Savci-Heijink,et al. Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent , 2017, Oncotarget.
[8] S. Dry,et al. Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model , 2017, Cell cycle.
[9] M. Michalski,et al. Macrophages and skeletal health , 2017, Pharmacology & therapeutics.
[10] D. Heymann,et al. Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization. , 2017, Cancer letters.
[11] Qiaojun He,et al. All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages , 2017, Cancer Immunology Research.
[12] T. Mcclanahan,et al. Patterns of PD‐1, PD‐L1, and PD‐L2 expression in pediatric solid tumors , 2017, Pediatric blood & cancer.
[13] R. Gillies,et al. Cancer‐associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF‐κB activation , 2017, International journal of cancer.
[14] Bohua Chen,et al. Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway , 2017, Oncotarget.
[15] Dazhi Yu,et al. Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients , 2017, International immunopharmacology.
[16] F. Verrecchia,et al. Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip. , 2017, European journal of cell biology.
[17] N. McGranahan,et al. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.
[18] D. Heymann,et al. Cancer stem cells in osteosarcoma. , 2017, Cancer letters.
[19] R. Cancedda,et al. Mesenchymal Stem Cell‐Derived Extracellular Vesicles as Mediators of Anti‐Inflammatory Effects: Endorsement of Macrophage Polarization , 2017, Stem cells translational medicine.
[20] T. Lagerweij,et al. Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression , 2017, Clinical Cancer Research.
[21] Dongxi Xiang,et al. Prognostic value of inflammation-based scores in patients with osteosarcoma , 2016, Scientific Reports.
[22] I. Endo,et al. Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug , 2016, Oncotarget.
[23] J. Rosocha,et al. Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment , 2016, Journal of inflammation research.
[24] M. Schilham,et al. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy , 2016, Cancer Immunology, Immunotherapy.
[25] S. Avnet,et al. Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion , 2016, PloS one.
[26] M. Heymann,et al. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma , 2016, Oncotarget.
[27] Y. Mo,et al. Mesenchymal Stem/Stromal Cells under Stress Increase Osteosarcoma Migration and Apoptosis Resistance via Extracellular Vesicle Mediated Communication , 2016, PloS one.
[28] Dorian Obino,et al. Inflammatory Osteoclasts Prime TNFα‐Producing CD4+ T Cells and Express CX3CR1 , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[29] M. Heymann,et al. Drugs in early clinical development for the treatment of osteosarcoma , 2016, Expert opinion on investigational drugs.
[30] M. Heymann,et al. RANK–RANKL signalling in cancer , 2016, Bioscience reports.
[31] B. Tang,et al. In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma. , 2016, Oncology letters.
[32] U. Oppermann,et al. Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours , 2016, Clinical Sarcoma Research.
[33] X. Zang,et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma , 2016, Scientific Reports.
[34] N. Baldini,et al. Multimodal transfer of MDR by exosomes in human osteosarcoma. , 2016, International journal of oncology.
[35] C. Fan,et al. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3 , 2016, Oncotarget.
[36] K. Ohashi,et al. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma , 2016, PloS one.
[37] G. Freeman,et al. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. , 2016, Immunity.
[38] Qing-lin Han,et al. CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. , 2016, International immunopharmacology.
[39] P. Brousset,et al. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] S. Molyneux,et al. RANKL blockade prevents and treats aggressive osteosarcomas , 2015, Science Translational Medicine.
[41] Florian Engert,et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency , 2015, Nature Communications.
[42] M. Donia,et al. Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer , 2015, Molecular oncology.
[43] Yin Sj,et al. Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice. , 2015, Genetics and molecular research : GMR.
[44] A. Patiño-García,et al. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. , 2015, Cancer letters.
[45] C. Jiang,et al. Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response. , 2015, Genetics and molecular research : GMR.
[46] M. Miyazaki,et al. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma. , 2015, Oncology reports.
[47] Ling-ling Sun,et al. Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells. , 2015, International immunopharmacology.
[48] A. Dietz,et al. Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+ HLA-DRlo/neg) found in aggressive pediatric sarcoma patients , 2015, Journal of Immunotherapy for Cancer.
[49] Tao Liu,et al. Pre-operative lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma , 2015, FEBS open bio.
[50] D. Heymann,et al. Interleukin‐34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment , 2015, International Journal of Cancer.
[51] L. Diller,et al. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma , 2015, Cancer Immunology, Immunotherapy.
[52] R. Hoffman. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts , 2015, Nature Reviews Cancer.
[53] E. Álava,et al. Bone microenvironment signals in osteosarcoma development , 2015, Cellular and Molecular Life Sciences.
[54] W. Weichert,et al. Establishment of a patient-derived orthotopic osteosarcoma mouse model , 2015, Journal of Translational Medicine.
[55] J. Blattman,et al. Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions , 2015, Journal of immunotherapy.
[56] A. L. Bosch,et al. CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study , 2015, Oncoimmunology.
[57] Qiyu Zhang,et al. Bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion , 2015, World Journal of Surgical Oncology.
[58] Yue Zhou,et al. Expression of programmed death 1 is correlated with progression of osteosarcoma , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[59] A. L. Bosch,et al. Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization , 2015, Annals of Surgical Oncology.
[60] Y. Kimura,et al. Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and/or G1 arrest in tumor cells. , 2015, European journal of pharmacology.
[61] B. Fuchs,et al. RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward? , 2014, Oncology.
[62] M. Ross,et al. Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics , 2014, Genome Medicine.
[63] Yongwon Choi,et al. Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond , 2014, Front. Immunol..
[64] David M. Thomas,et al. Translational biology of osteosarcoma , 2014, Nature Reviews Cancer.
[65] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[66] Carl R Walkley,et al. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? , 2014, Bone.
[67] G. Nielsen,et al. Programmed Cell Death Ligand 1 Expression in Osteosarcoma , 2014, Cancer Immunology Research.
[68] M. Schilham,et al. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ , 2014, Journal of experimental & clinical cancer research : CR.
[69] E. Kleinerman,et al. Aerosol interleukin‐2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis , 2014, Pediatric blood & cancer.
[70] S. Rosenberg,et al. Exploiting the curative potential of adoptive T‐cell therapy for cancer , 2014, Immunological reviews.
[71] G. Hannon,et al. Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.
[72] Yingze Zhang,et al. B7-H3 is Overexpressed in Patients Suffering Osteosarcoma and Associated with Tumor Aggressiveness and Metastasis , 2013, PloS one.
[73] C. Lewis,et al. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. , 2013, Cancer research.
[74] A. Evdokiou,et al. The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. , 2012, Biochimica et biophysica acta.
[75] S. Fallarini,et al. Invariant NKT cells increase drug‐induced osteosarcoma cell death , 2012, British journal of pharmacology.
[76] Zhaoxu Li. Potential of human γδ T cells for immunotherapy of osteosarcoma , 2012, Molecular Biology Reports.
[77] Qiang Xu,et al. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T‐cell‐mediated cytotoxicity by zoledronate , 2012, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[78] S. Chevalier,et al. Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling , 2012, Stem cells.
[79] H. Tsuchiya,et al. Anti-TGF-β Antibody Combined with Dendritic Cells Produce Antitumor Effects in Osteosarcoma , 2012, Clinical orthopaedics and related research.
[80] S. Gottschalk,et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma , 2011, Cancer Gene Therapy.
[81] D. Scherman,et al. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[82] D. Heymann,et al. Bone sarcomas: pathogenesis and new therapeutic approaches , 2011 .
[83] Qiang Xu,et al. IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway. , 2011, International immunopharmacology.
[84] Anne-Marie Cleton-Jansen,et al. Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents , 2011, Clinical Cancer Research.
[85] P. Hogendoorn,et al. Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad , 2011, Stem cells.
[86] L. Vermeulen,et al. Cancer stem cell niche: the place to be. , 2011, Cancer research.
[87] Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells , 2011, Cancer Immunology, Immunotherapy.
[88] D. Heymann,et al. Mifamurtide for the treatment of nonmetastatic osteosarcoma , 2011, Expert opinion on pharmacotherapy.
[89] S. Dow,et al. Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. , 2010, Journal of veterinary internal medicine.
[90] M. Heymann,et al. Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence , 2010, PloS one.
[91] S. Gordon,et al. Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.
[92] D. Heymann,et al. Interleukin‐34 is expressed by giant cell tumours of bone and plays a key role in RANKL‐induced osteoclastogenesis , 2010, The Journal of pathology.
[93] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[94] H. Heslop,et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[95] D. Heymann,et al. Mechanisms of bone repair and regeneration. , 2009, Trends in molecular medicine.
[96] N. Athanasou,et al. Canonical and non-canonical pathways of osteoclast formation. , 2009, Histology and histopathology.
[97] B. Trinité,et al. Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. , 2008, Cancer research.
[98] R. Zhao,et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell stem cell.
[99] D. Heymann,et al. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases , 2008, Expert review of anticancer therapy.
[100] E. Madon,et al. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. , 2007, Cellular immunology.
[101] J. Allison,et al. The B7 Family and Cancer Therapy: Costimulation and Coinhibition , 2007, Clinical Cancer Research.
[102] D. Heymann,et al. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases , 2007, Cellular and Molecular Life Sciences.
[103] B. Le Goff,et al. Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.
[104] H. Takayanagi. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems , 2007, Nature Reviews Immunology.
[105] D. Heymann,et al. Osteosarcoma: current status of immunotherapy and future trends (Review). , 2006, Oncology reports.
[106] J. Pollard,et al. Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.
[107] S. Théoleyre,et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma , 2005, BMC Cancer.
[108] S. Théoleyre,et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.
[109] D. Heymann,et al. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. , 2004, Trends in molecular medicine.
[110] D. Heymann,et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.
[111] I. Fidler,et al. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.
[112] D. Heymann,et al. Osteoclastic acidification pathways during bone resorption. , 2002, Bone.
[113] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[114] R. Steinman,et al. TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.
[115] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[116] R. Hoffman. Patient-Derived Mouse Models of Cancer , 2017, Molecular and Translational Medicine.
[117] S. Kiany,et al. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect. , 2016, Methods in molecular biology.
[118] S. Gottschalk,et al. Genetically modified T-cell therapy for osteosarcoma. , 2014, Advances in experimental medicine and biology.
[119] Dean Anthony Lee,et al. Natural killer cells for osteosarcoma. , 2014, Advances in experimental medicine and biology.
[120] M. Padrines,et al. Proteoglycans and osteolysis. , 2012, Methods in molecular biology.
[121] S. Ferrari,et al. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. , 2008, International journal of oncology.
[122] Y. Konttinen,et al. Mast cells in atherosclerosis as a source of the cytokine RANKL , 2006, Clinical chemistry and laboratory medicine.
[123] G. Parmiani,et al. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype , 2005, Cancer Immunology, Immunotherapy.
[124] F. Levi-Schaffer,et al. Osteoblast-like cell line maintains in vitro rat peritoneal mast cell viability and functional activity. , 1990, Immunology.